Ina Pharmaceuti Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ina Pharmaceuti (US): 2 reconciled FDA prescription therapies, $35.8M 2024 CMS Part D & Medicaid spend, and $3,750 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$35.8M
2024 Medicare Part D Spend$5.1M
2024 Medicaid Spend$30.6M
California HCAI SB 17 FilingsSpecialty launch notice ($3,750 intro WAC)